Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
QOL Medical, LLC
With
Arnold Palmer Hospital for Children
Baylor College of Medicine
Nationwide Children's Hospital
Ann & Robert H Lurie Children's Hospital of Chicago
University of Mississippi Medical Center
Children's Hospital and Research Center at Oakland
Columbia University
Children's Hospital Los Angeles
Children's Hospital and Health System Foundation, Wisconsin
Children's Center for Digestive Healthcare, LLC
Massachusetts General Hospital
Duke University
Johns Hopkins University
Children's Hospital of Philadelphia
Children's Mercy Hospital Kansas City
Children's Hospital Colorado
Riley Children's Hospital
Primary Children's Hospital
State University of New York - Downstate Medical Center
Age
0–18
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Must be 18 years of age or younger.
A primary clinical diagnosis of chronic idiopathic diarrhea or chronic abdominal pain for at least 4 weeks.
English or Spanish speaking subjects and parent(s)/guardian only.
Parental consent from one parent/guardian and also subject assent when appropriate based on individual IRB requirements.
You may not be if
Any condition(s) or finding(s) that in the opinion of the principal investigator suggests an alternative diagnosis for his/her gastrointestinal symptoms.
Abdominal pain primarily related to constipation.
Suspected gastrointestinal infectious disease.
No current use of sacrosidase (Sucraid® Oral Solution).
Known gastrointestinal disease such as celiac disease.
Prior consumption of an investigational medication within the last 4 weeks.
Antibiotics in the last 2 weeks, and no history of viral gastroenteritis within that same period of time.
Known Hepatitis B or C infection (positive HBsAg or HCV within 6 months of enrollment) or Subject-Pugh Class C liver disease of any cause, HIV infection, tuberculosis, Clostridia difficile co-infection, cancer or systemic infections.
Severe neurologic impairment that would prevent them from reporting a history of abdominal pain.
Receiving or received biologic therapies (including infliximab, adalimumab, natalizumab) within 3 months prior to or at enrollment.
Present or past use of immune modulators therapy (e.g., azathioprine, 6MP, methotrexate).
Planned or previous abdominal surgery (e.g., bowel resection).
Subjects with severe, uncontrolled systemic diseases.
Presence of clinical alarm signs, including hypotension, anemia requiring blood transfusions, altered mental status, or inability to tolerate food and/or fluids by mouth.
